SUPN News and Press, Supernus Pharmaceuticals Inc. From 10/11/21

Supernus Pharmaceuticals Inc ( NASDAQ: SUPN ) recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals ( NASDAQ: ADMS ). Supernus is to purchase this company a tender offer that was worth about $8.10 per share. The aggregate was roug...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors in  Adamas Pharmaceuticals (NASDAQ: ADMS ) are off to a great week. The pharma play is getting picked up as part of an acquisition with biopharma company  Supernus (NASDAQ: SUPN ). The news thi...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, traders! We’re kicking off the week with a look at the biggest pre-market stock market movers for Monday! Source: f11photo/Shutterstock.com There’s plenty of news moving stock today with ...

Acquisition of two marketed products diversifies and accelerates revenue and cash flow Expected to be significantly accretive in 2022 Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructure Total consideration up to $9...

ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administra...

ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company’s management w...

Supernus reported a solid earnings beat for its most recent earnings report, Q2 2021 issued on 08/04/2021. Its product profile is growing nicely with recent acquisitions, new product launches and candidates facing near-term FDA review. The company has a strong liquidity position t...

Image source: The Motley Fool. Supernus Pharmaceuticals, inc (NASDAQ: SUPN) Q2 2021 Earnings Call Aug 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Supernus Pharmaceuticals, inc (SUPN) Q2 2021 Earnings Call Tra...

Supernus Pharmaceuticals, Inc. (SUPN) Q2 2021 Earnings Conference Call August 04, 2021 04:30 PM ET Company Participants Peter Vozzo - Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Jim Kelly - Chief Financial Officer Conference Call Participants David Steinberg - Jefferi...

Supernus Pharmaceuticals (NASDAQ:SUPN): Q2 GAAP EPS of $0.43 beats by $0.23. Revenue of $141.3M (+11.5% Y/Y) beats by $5.8M. As of June 30, 2021, the Company had $855.3 million in cash, cash equivalents, current and long-term marketable securities, compared to $772.9 million as of December 31...